SCHEMBL14840342

SCHEMBL14840342

Fc1c[c]c(-c2ccncn2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.40
MAPK9 P45984 3/20 0.40
MAPK10 P53779 2/20 0.40
MAPK11 Q15759 2/20 0.40
MAP4K4 O95819 2/20 0.39
EGFR P00533 2/20 0.39
FRK P42685 2/20 0.39
CSNK1A1 P48729 2/20 0.39
CASP6 P55212 1/20 0.34
GRM1 Q13255 1/20 0.34
HSP90AA1 P07900 1/20 0.32
CYP2D6 P10635 1/20 0.32
KCNH3 Q9ULD8 1/20 0.31
GSK3B P49841 2/20 0.31
F2 P00734 1/20 0.30
MAPK13 O15264 1/20 0.30
MAPK12 P53778 1/20 0.30
DCLK1 O15075 1/20 0.30
PRKD3 O94806 1/20 0.30
PRKACA P17612 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14840926 0.77 MAPK9 (0.33) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL28163212 0.76 KDM4E (0.46) MAPK14HSP90AA1FLT3
SCHEMBL14840276 0.74 MAPK9 (0.36) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL8328581 0.73 MAPK14 (0.41) MAPK14MAPK9MAPK10MAPK11MAPK13
SCHEMBL1445257 0.71 MAPK14 (0.57) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL29415406 0.71 MAPK14 (0.57) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL712064 0.70 MAPK14 (0.37) MAPK14MAPK9MAPK10MAPK11HSP90AA1
SCHEMBL29391733 0.69 MAPT (0.46) MAPK14MAPK9MAPK10MAPK11MAP4K4
SCHEMBL1586841 0.69 KMT2A (0.35)
SCHEMBL2814353 0.68 HSP90AA1 (0.52) MAPK14MAPK9MAPK10MAPK11MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-16 US disclosed
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICALS CO (JP) 2021-07-08 US disclosed
US-9440990-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-09-13 US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 EP disclosed
US-20150376205-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-12-31 US disclosed
US-8648079-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-02-11 US disclosed
US-20130090341-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376205-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, PSEN1, HTT MAPK14 1172/4885MAPK9 1147/4885MAPK10 738/4885
US-11174272-B2 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases SNCA, HTT, PSEN1 MAPK14 956/4885MAPK9 948/4885MAPK10 605/4885
US-20130090341-A1 HETEROCYCLIC COMPOUNDS HTT, NQO1, BDNF MAPK14 1052/4885MAPK9 1081/4885MAPK10 815/4885
US-20210206781-A1 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SNCA, HTT, PSEN1 MAPK14 956/4885MAPK9 948/4885MAPK10 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.